SCCS Preliminary Opinion on 4-MBC
In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. As 4-MBC (UV-filter) was included in the higher priority group, the European Commission asked the SCCS to carry out a safety assessment on this ingredient. The preliminary version of the requested opinion was published.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate

4-MBC

The aromatic compound 4-Methylbenzylidene camphor (chemical name 3-(4′-methylbenzylidene)-camphor / Enzacamene), commonly called 4-MBC, is an ingredient used as a light stabilizer, UV absorber and UV filter in cosmetics and personal care products. According to the Cosmetics Regulation (No. 1223/2009), 4-MBC is included in the list of UV filters allowed in cosmetic products (Annex VI, entry 18). 4-Methylbenzylidene Camphor can be used as an UV filter in sunscreen products at concentrations up to 4% in ready for use preparation.

The safety of this ingredient has been assessed several times by the Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers (SCCNFP, 1998, 2001 and 2004) and by the Scientific Committee on Consumer Products (SCCP, 2006 and 2008). In 2008, the SCCP concluded that “4-MBC can be considered safe for use in finished cosmetic products (whole body application) at a concentration of up to 4%“. Moreover, the SCCP stated that “it must be emphasized that this opinion is restricted to the safety evaluation of 4-MBC after dermal application of a cosmetic product containing this UV filter“, which means that other exposure scenarios (inhalation and oral route) were not covered in such safety assessment and risk could not be excluded.

NEW SCCS PRELIMINARY OPINION

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B). The public call for data for the considered higher priority substances was carried out in 2019. 4-Methylbenzylidene camphor was included in Group A. (see previous post)

During the call for data, stakeholders submitted scientific evidence to demonstrate the safety of 4-MBC as an UV-filter in cosmetic products. The European Commission asked the Scientific Committee on Consumer Safety (SCCS) to carry out a safety assessment on 4-MBC considering the data submitted.

The SCCS published its preliminary opinion on 4-MBC and stated that it “cannot concluded on the safety of 4-MBC, because the information provided is insufficient to fully evaluate potential genotoxicity”. Because of this, it was not possible for the SCCS to derive a maximum concentration for safe use of 4-MBC.

The Committee considers that there is insufficient evidence that this ingredient may act as an endocrine disruptor and has effects on both the thyroid and estrogen systems. Effects on thyroid and estrogen systems were observed at oral exposure levels of 50 and 100 mg/kg body weight/day, respectively.

The SCCS preliminary opinion is open for comments until 28 February 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Products (SCCP). Opinion on 4-Methylbenzylidene camphor (4-MBC). COLIPA nº S60. SCCP/1184/08. 2008.
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on 4-MEthylbenzylidene camphor (4-MBC). SCCS/1640/21. Preliminary version. 2021.

further
reading

cosmetic products

Citral under review: SCCS’s Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »